CO6400198A2 - Composiciones y metodos novedosos - Google Patents
Composiciones y metodos novedososInfo
- Publication number
- CO6400198A2 CO6400198A2 CO11009236A CO11009236A CO6400198A2 CO 6400198 A2 CO6400198 A2 CO 6400198A2 CO 11009236 A CO11009236 A CO 11009236A CO 11009236 A CO11009236 A CO 11009236A CO 6400198 A2 CO6400198 A2 CO 6400198A2
- Authority
- CO
- Colombia
- Prior art keywords
- methods
- new compositions
- rv1753c
- protein sequence
- relates
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 101100030444 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) PPE24 gene Proteins 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 239000012634 fragment Substances 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 201000008827 tuberculosis Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/35—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Mycobacteriaceae (F)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8369208P | 2008-07-25 | 2008-07-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6400198A2 true CO6400198A2 (es) | 2012-03-15 |
Family
ID=41172233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO11009236A CO6400198A2 (es) | 2008-07-25 | 2011-01-27 | Composiciones y metodos novedosos |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US9315556B2 (https=) |
| EP (1) | EP2315597B1 (https=) |
| JP (1) | JP5824360B2 (https=) |
| KR (2) | KR20110060891A (https=) |
| CN (2) | CN102164612B (https=) |
| AU (1) | AU2009273133B2 (https=) |
| BR (1) | BRPI0916705A2 (https=) |
| CA (1) | CA2731549C (https=) |
| CO (1) | CO6400198A2 (https=) |
| CY (1) | CY1119737T1 (https=) |
| EA (1) | EA022203B1 (https=) |
| ES (1) | ES2647321T3 (https=) |
| HR (1) | HRP20171694T1 (https=) |
| HU (1) | HUE037121T2 (https=) |
| IL (1) | IL210588A0 (https=) |
| LT (1) | LT2315597T (https=) |
| MX (1) | MX2011000981A (https=) |
| NO (1) | NO2315597T3 (https=) |
| PL (1) | PL2315597T3 (https=) |
| PT (1) | PT2315597T (https=) |
| SG (1) | SG10201505149WA (https=) |
| SI (1) | SI2315597T1 (https=) |
| UA (1) | UA107180C2 (https=) |
| WO (1) | WO2010010180A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009273132B2 (en) | 2008-07-25 | 2015-09-03 | Glaxo Group Limited | The tuberculosis Rv2386c protein, compositions and uses thereof |
| GB201116248D0 (en) | 2011-09-20 | 2011-11-02 | Glaxosmithkline Biolog Sa | Liposome production using isopropanol |
| WO2013090897A1 (en) * | 2011-12-15 | 2013-06-20 | The Trustees Of The University Of Pennsylvania | Using adaptive immunity to detect drug resistance |
| CN103467582A (zh) * | 2012-06-08 | 2013-12-25 | 同济大学 | 结核杆菌重要抗原的高通量筛选及其在结核病诊断中的应用 |
| GB201405921D0 (en) * | 2014-04-02 | 2014-05-14 | Glaxosmithkline Biolog Sa | Novel methods for inducing an immune response |
| US10695424B2 (en) | 2016-12-07 | 2020-06-30 | Glaxosmithkline Biologicals S.A. | Method of making a liposome composition |
| GB201621686D0 (en) | 2016-12-20 | 2017-02-01 | Glaxosmithkline Biologicals Sa | Novel methods for inducing an immune response |
| GB201707700D0 (en) | 2017-05-12 | 2017-06-28 | Glaxosmithkline Biologicals Sa | Dried composition |
| GB2600653B (en) | 2017-05-30 | 2022-11-02 | Glaxosmithkline Biologicals Sa | Novel methods |
| BR112020010790A2 (pt) | 2017-12-01 | 2020-11-10 | Glaxosmithkline Biologicals S.A. | purificação da saponina |
| WO2020214961A1 (en) * | 2019-04-17 | 2020-10-22 | Codiak Biosciences, Inc. | Methods of treating tuberculosis |
| WO2020245207A1 (en) | 2019-06-05 | 2020-12-10 | Glaxosmithkline Biologicals Sa | Saponin purification |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4016146A (en) * | 1974-12-10 | 1977-04-05 | Biological Developments, Inc. | Phenethylamine antigenic conjugates, their preparation, antibodies, and use |
| CA2138997C (en) | 1992-06-25 | 2003-06-03 | Jean-Paul Prieels | Vaccine composition containing adjuvants |
| US6458366B1 (en) | 1995-09-01 | 2002-10-01 | Corixa Corporation | Compounds and methods for diagnosis of tuberculosis |
| US6592877B1 (en) | 1995-09-01 | 2003-07-15 | Corixa Corporation | Compounds and methods for immunotherapy and diagnosis of tuberculosis |
| US6613881B1 (en) | 1997-05-20 | 2003-09-02 | Corixa Corporation | Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use |
| PL202844B1 (pl) | 1998-04-07 | 2009-07-31 | Corixa Corp | Immunogeniczny polipeptyd, polinukleotyd, polipeptyd, kompozycja farmaceutyczna, wektor ekspresji, kompozycja szczepionki, polipeptyd do stosowania w leczeniu lub zapobieganiu infekcjom Mycobacterium tuberculosis, polinukleotyd do stosowania w leczeniu lub zapobieganiu infekcjom Mycobacterium tuberculosis i sposób wytwarzania polipeptydu |
| US7083796B2 (en) | 2000-06-20 | 2006-08-01 | Corixa Corporation | Fusion proteins of mycobacterium tuberculosis |
| US6291013B1 (en) * | 1999-05-03 | 2001-09-18 | Southern Biosystems, Inc. | Emulsion-based processes for making microparticles |
| WO2001019993A2 (en) | 1999-09-17 | 2001-03-22 | University Of Maryland, Baltimore | Virulence genes of m. marinum and m. tuberculosis |
| EP1229931A4 (en) | 1999-10-07 | 2003-05-28 | Corixa Corp | FUSION PROTEINS FROM MYCOBACTERIUM TUBERCULOSIS |
| AU2001241738A1 (en) | 2000-02-25 | 2001-09-03 | Corixa Corporation | Compounds and methods for diagnosis and immunotherapy of tuberculosis |
| US20040121322A9 (en) | 2001-02-22 | 2004-06-24 | Cole Stewart T. | Comparative mycobacterial genomics as a tool for identifying targets for the diagnosis, prophylaxis or treatment of mycobacterioses |
| US7026465B2 (en) | 2002-02-15 | 2006-04-11 | Corixa Corporation | Fusion proteins of Mycobacterium tuberculosis |
| US20030236393A1 (en) * | 2002-03-22 | 2003-12-25 | United States Of America Dept Of Vetrans Affairs | Virulence genes of M. marinum and M. tuberculosis |
| US7424370B2 (en) * | 2004-02-06 | 2008-09-09 | Council Of Scientific And Industrial Research | Computational method for identifying adhesin and adhesin-like proteins of therapeutic potential |
| DK2457926T3 (da) * | 2005-04-29 | 2015-01-05 | Glaxosmithkline Biolog Sa | Ny fremgangsmåde til forebyggelse eller behandling af M. tuberkulose-infektion |
| WO2008007942A1 (en) | 2006-07-10 | 2008-01-17 | Het Nederlands Kanker Instituut | Means and methods for manipulating sequential phagolysomal-cytosolic translocation of mycobacteria, and uses thereof |
| PL2137210T3 (pl) * | 2007-03-02 | 2017-06-30 | Glaxosmithkline Biologicals Sa | Nowy sposób i kompozycje |
| AU2009273130B2 (en) | 2008-07-25 | 2014-10-16 | Glaxo Group Limited | Novel compositions and methods |
| AU2009273132B2 (en) | 2008-07-25 | 2015-09-03 | Glaxo Group Limited | The tuberculosis Rv2386c protein, compositions and uses thereof |
| WO2010010178A1 (en) | 2008-07-25 | 2010-01-28 | Glaxosmithkline Biologicals S.A | The tuberculosis rv2707c protein, compositions and uses thereof |
| MX2011011186A (es) | 2009-04-24 | 2012-02-13 | Una vacuna antituberculosis tb para evitar la reactivacion. | |
| WO2010132112A2 (en) | 2009-05-14 | 2010-11-18 | Wisconsin Alumni Research Foundation | Immunogenic compositions against tuberculosis |
| BR112012018669A2 (pt) | 2010-01-27 | 2017-09-05 | Glaxosmithkline Biologicals Sa | Proteína rv3616c modificada, uso de uma proteína rv3616c modificada, polinucleotídeo, uso de um polinucleotídeo, composição farmacêutica, composição imunogênica, proteína de fusão, e, polipeptídeo. |
-
2009
- 2009-07-24 CA CA2731549A patent/CA2731549C/en active Active
- 2009-07-24 AU AU2009273133A patent/AU2009273133B2/en not_active Ceased
- 2009-07-24 HR HRP20171694TT patent/HRP20171694T1/hr unknown
- 2009-07-24 US US13/055,775 patent/US9315556B2/en active Active
- 2009-07-24 PT PT97810584T patent/PT2315597T/pt unknown
- 2009-07-24 LT LTEP09781058.4T patent/LT2315597T/lt unknown
- 2009-07-24 PL PL09781058T patent/PL2315597T3/pl unknown
- 2009-07-24 JP JP2011519187A patent/JP5824360B2/ja active Active
- 2009-07-24 SI SI200931748T patent/SI2315597T1/sl unknown
- 2009-07-24 ES ES09781058.4T patent/ES2647321T3/es active Active
- 2009-07-24 KR KR1020117004475A patent/KR20110060891A/ko not_active Ceased
- 2009-07-24 UA UAA201100362A patent/UA107180C2/uk unknown
- 2009-07-24 MX MX2011000981A patent/MX2011000981A/es active IP Right Grant
- 2009-07-24 CN CN200980138416.7A patent/CN102164612B/zh active Active
- 2009-07-24 HU HUE09781058A patent/HUE037121T2/hu unknown
- 2009-07-24 WO PCT/EP2009/059586 patent/WO2010010180A1/en not_active Ceased
- 2009-07-24 SG SG10201505149WA patent/SG10201505149WA/en unknown
- 2009-07-24 EA EA201100071A patent/EA022203B1/ru not_active IP Right Cessation
- 2009-07-24 EP EP09781058.4A patent/EP2315597B1/en active Active
- 2009-07-24 KR KR1020167001375A patent/KR20160013262A/ko not_active Ceased
- 2009-07-24 NO NO09781058A patent/NO2315597T3/no unknown
- 2009-07-24 CN CN201711306994.XA patent/CN108059660A/zh active Pending
- 2009-07-24 BR BRPI0916705A patent/BRPI0916705A2/pt not_active Application Discontinuation
-
2011
- 2011-01-12 IL IL210588A patent/IL210588A0/en unknown
- 2011-01-27 CO CO11009236A patent/CO6400198A2/es not_active Application Discontinuation
-
2016
- 2016-03-11 US US15/067,469 patent/US9750794B2/en not_active Expired - Fee Related
-
2017
- 2017-11-13 CY CY20171101185T patent/CY1119737T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6351811A2 (es) | La proteina de tuberculosis rv2386c, composiciones y usos de la misma | |
| CO6400198A2 (es) | Composiciones y metodos novedosos | |
| CO6341637A2 (es) | \\\\\\\"composiciones y metodos novedosos\\\\\\\" | |
| AR125326A2 (es) | Composiciones de neisseria meningitidis y métodos de las mismas | |
| CR11580A (es) | Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf | |
| CO2020001872A2 (es) | Preparación de exosomas terapéuticos mediante el uso de proteínas de membrana | |
| CY1122824T1 (el) | Πρωτεϊνες συντηξης και εμβολια συνδυασμου | |
| UY33204A (es) | Metodos y composiciones usando polipeptidos de fusion de fgf23 | |
| CO6491045A2 (es) | Composiciones de proteina f de virus sincitial respiratorio (rsv) y metodos para producir las mismas | |
| CL2013003416A1 (es) | Secuencia de peptidos quiméricos que comprende dsspl o dasph composiciones , usos y metodo para mejorar metabolismo de glucosa. | |
| BRPI0715396B8 (pt) | método de produção de uma composição para vacina | |
| GT200900163A (es) | Nuevos compuestos y sus efectos sobre el conductismo de la alimentacion. | |
| CL2010001426A1 (es) | Compuestos derivados de triciclos, inhibidores de la proteina quinasa; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades oncologicas e inmunologicas. | |
| CU20080133A7 (es) | Composiciones y métodos de uso para anticuerpos de dickkopf-1 | |
| PE20142451A1 (es) | Composiciones de conjugados de xten y metodos para realizar las mismas | |
| EA201270625A1 (ru) | Лиофилизированная композиция терапевтического пептидного антитела | |
| CL2009000402A1 (es) | Compuestos derivados de 2-amino-acetamida sustituida; composicion farmaceutica; utiles en el tratamiento de enfermedades pulmonares, enfermedad reumatica, enfermedad autoinmune, entre otras. | |
| BR112015013525A2 (pt) | método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão | |
| CL2010001569A1 (es) | Pestivirus atenuado mediante la mutacion conjunta de las proteinas e erns y n pro.composicion inmunogenica y vacuna que lo comprende, metodo para atenuar pestivirus basado en la supresion de la dimerizacion de la proteina e rns y la ianactivacion de la proteina n pro. | |
| EA201171494A1 (ru) | Миметики белка smac | |
| AR083126A1 (es) | Composicion vacunal para el control de las infestaciones por ectoparasitos | |
| ES2585328T3 (es) | Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis | |
| MX366906B (es) | Purificacion de iduronato-2-sulfatasa. | |
| MX2011006846A (es) | Virus de fiebre porcina clasico recombinante (csfv) comprendiendo una proteina e2 modificada y metodos para generar dicho csfv. | |
| BR112014007675A2 (pt) | tratamento de doença articular degenerativa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |